MaxCyte, Inc. Total Voting Rights (3554Y)
02 Januar 2024 - 10:23AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 3554Y
MaxCyte, Inc.
02 January 2024
MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights
ROCKVILLE, MD, January 2, 2024 - MaxCyte Inc., (NASDAQ: MXCT;
LSE: MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics and innovative bioprocessing applications , announces
that pursuant to its block admission facility, since 30 November
2023 it has issued 251,799 of common stock, $0.01 par, of the
Company ("Common Stock") in satisfaction of the exercise of share
options.
Total voting rights
As at 31 December 2023, the total issued stock capital of the
Company following the recent issue of the new Common Stock is
103,961,670 shares of Common Stock. Shareholders in the Company may
use this figure as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the stock capital of the
Company.
For further information, please contact:
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
ICR Consilium maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation(R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology platform, as well as
scientific, technical, and regulatory support, we aim to guide them
on their journey to transform human health. Learn more at
maxcyte.com and follow us on Twitter and LinkedIn .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRQKBBBCBKKKDK
(END) Dow Jones Newswires
January 02, 2024 04:23 ET (09:23 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024